Regulation of CD4+NKG2D+ Th1 cells in patients with metastatic melanoma treated with sorafenib: Role of IL-15Rα and NKG2D triggering

Ana I. Romero, Nathalie Chaput, Vichnou Poirier-Colame, Sylvie Rusakiewicz, Nicolas Jacquelot, Kariman Chaba, Erwan Mortier, Yannick Jacques, Sophie Caillat-Zucman, Caroline Flament, Anne Caignard, Meriem Messaoudene, Anne Aupérin, Philippe Vielh, Philippe Dessen, Camillo Porta, Christine Mateus, Maha Ayyoub, Danila Valmori, Alexander EggermontCaroline Robert, Laurence Zitvogel

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

38 Citaten (Scopus)


Beyond cancer-cell intrinsic factors, the immune status of the host has a prognostic impact on patients with cancer and influences the effects of conventional chemotherapies. Metastatic melanoma is intrinsically immunogenic, thereby facilitating the search for immune biomarkers of clinical responses to cytotoxic agents. Here, we show that a multi-tyrosine kinase inhibitor, sorafenib, upregulates interleukin (IL)-15Rα in vitro and in vivo in patients with melanoma, and in conjunction with natural killer (NK) group 2D (NKG2D) ligands, contributes to the Th1 polarization and accumulation of peripheral CD4+NKG2D+ T cells. Hence, the increase of blood CD4+NKG2D+ T cells after two cycles of sorafenib (combined with temozolomide) was associated with prolonged survival in a prospective phase I/II trial enrolling 63 patients with metastatic melanoma who did not receive vemurafenib nor immune checkpoint-blocking antibodies. In contrast, in metastatic melanoma patients treated with classical treatment modalities, this CD4+NKG2D+ subset failed to correlate with prognosis. These findings indicate that sorafenib may be used as an "adjuvant" molecule capable of inducing or restoring IL-15Rα/IL-15 in tumors expressing MHCclass I-related chain A/B (MICA/B) and on circulating monocytes of responding patients, hereby contributing to the bioactivity of NKG2D+ Th1 cells.

Originele taal-2Engels
Pagina's (van-tot)68-80
Aantal pagina's13
TijdschriftCancer Research
Nummer van het tijdschrift1
StatusGepubliceerd - 1 jan. 2014
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Regulation of CD4+NKG2D+ Th1 cells in patients with metastatic melanoma treated with sorafenib: Role of IL-15Rα and NKG2D triggering'. Samen vormen ze een unieke vingerafdruk.

Citeer dit